These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8065168)

  • 1. Infection of elderly patients receiving high dose cytarabine-based chemotherapy for induction treatment of acute myelogenous leukemia (AML).
    Nemunaitis J; Meyer W; Nemunaitis J; Taylor E; Riley C; Cooper B
    Leuk Res; 1994 Aug; 18(8):649-50. PubMed ID: 8065168
    [No Abstract]   [Full Text] [Related]  

  • 2. Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
    Bow EJ; Kilpatrick MG; Scott BA; Clinch JJ; Cheang MS
    Cancer; 1994 Jul; 74(1):52-60. PubMed ID: 8004583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High response rate for treatment with gemtuzumab ozogamicin and cytarabine in elderly patients with acute myeloid leukemia and favorable and intermediate-I cytogenetic risk.
    Tavor S; Rahamim E; Sarid N; Rozovski U; Gibstein L; Aviv F; Kirsner I; Naparstek E
    Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):438-43. PubMed ID: 23017331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
    Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postremission chemotherapy for adults with acute myelogenous leukemia: improved survival with high-dose cytarabine and daunorubicin consolidation treatment.
    Champlin R; Gajewski J; Nimer S; Vollset S; Landaw E; Winston D; Schiller G; Ho W
    J Clin Oncol; 1990 Jul; 8(7):1199-206. PubMed ID: 1694236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose cytarabine in acute myelogenous leukemia.
    Zittoun R
    Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():38-42. PubMed ID: 2653516
    [No Abstract]   [Full Text] [Related]  

  • 8. Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemia.
    Roboz GJ; Ritchie EK; Curcio T; Provenzano J; Carlin R; Samuel M; Wittenberg B; Mazumdar M; Christos PJ; Mathew S; Allen-Bard S; Feldman EJ
    Cancer; 2008 Nov; 113(9):2504-11. PubMed ID: 18825661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
    Sternberg DW; Aird W; Neuberg D; Thompson L; MacNeill K; Amrein P; Shulman LN
    Cancer; 2000 May; 88(9):2037-41. PubMed ID: 10813714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia.
    Decker RW; Ho WG; Champlin RE
    Cancer Treat Rep; 1987 Sep; 71(9):881-2. PubMed ID: 3476204
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
    Koller CA; Kantarjian HM; Feldman EJ; O'Brien S; Rios MB; Estey E; Keating M
    Cancer; 1999 Dec; 86(11):2246-51. PubMed ID: 10590364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation.
    Saito K; Nakamura Y; Aoyagi M; Waga K; Yamamoto K; Aoyagi A; Inoue F; Nakamura Y; Arai Y; Tadokoro J; Handa T; Tsurumi S; Arai H; Kawagoe Y; Gunnji H; Kitsukawa Y; Takahashi W; Furusawa S
    Int J Hematol; 2000 Apr; 71(3):238-44. PubMed ID: 10846828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acute myelogenous leukemia in the elderly.
    Champlin RE; Gajewski JL; Golde DW
    Semin Oncol; 1989 Feb; 16(1):51-6. PubMed ID: 2645650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-index dose not predict the development of pulmonary infection in acute myeloid leukemia patients undergoing consolidation chemotherapy with high-dose cytarabine.
    Kimura S; Wada H; Ishihara Y; Kawamura K; Sakamoto K; Yamasaki R; Ashizawa M; Machishima T; Sato M; Terasako K; Nakasone H; Kikuchi M; Okuda S; Kako S; Kanda J; Yamazaki R; Tanihara A; Nishida J; Kanda Y
    Hematology; 2014 Mar; 19(2):107-12. PubMed ID: 23683842
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
    Schoen MW; Woelich SK; Braun JT; Reddy DV; Fesler MJ; Petruska PJ; Freter CE; Lionberger JM
    Leuk Res; 2018 May; 68():72-78. PubMed ID: 29574395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Acute myeloid leukemia with poor prognosis: treatment with oral 4-demethoxydaunorubicin (idarubicin) and low-dose cytarabine via subcutaneous route].
    Helg C; Chapuis B; Grob JP; Pugin P
    Schweiz Med Wochenschr; 1990 Apr; 120(15):548-52. PubMed ID: 2336558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome.
    Estey EH; Kantarjian H; Keating M
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):1-5. PubMed ID: 8290966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of high-dose cytarabine as consolidation therapy for cytogenetically intermediate AML: a single center analysis].
    Zhao BB; Wang L; Tang W
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):229-32. PubMed ID: 22781615
    [No Abstract]   [Full Text] [Related]  

  • 20. Conventional dose cytosine arabinoside in combination chemotherapy for acute myelogenous leukemia.
    Lister TA; Rohatiner AZ; Bassan R; Gregory W; Willis L; Barnett MJ; Waxman J; Richards MA; Ganesan TS; Tucker J
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):53-4. PubMed ID: 3473683
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.